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Abstract Doxorubicin (Dox) is a very potent antineo-
plastic agent used against several types of cancer,
despite a cumulative cardiomyopathy that reduces the
therapeutic index for treatment. H9c2 myoblast cells
have been used as an in vitro model to study biochem-
ical alterations induced by Dox treatment on cardio-
myocyte cells. Despite the extensive work already
published, few data are available regarding morpholog-
ical alterations of H9c2 cells during Dox treatment. The
purpose of the present work was to evaluate Dox-
induced morphological alterations in H9c2 myoblasts,
focusing especially on the nuclei, mitochondria, and
structural fibrous proteins. Treatment of H9c2 cell with
low concentrations of Dox causes alterations in fibrous
structural proteins including the nuclear lamina and
sarcomeric cardiac myosin, as well as mitochondrial
depolarization and fragmentation, membrane blebbing
with cell shape changes, and phosphatidylserine exter-
nalization. For higher Dox concentrations, more pro-
found alterations are evident, including nuclear swelling
with disruption of nuclear membrane structure, mito-
chondrial swelling, and extensive cytoplasm vacuoliza-
tion. The results obtained indicate that Dox causes
morphological alterations in mitochondrial, nuclear, and
fibrous protein structures in H9c2 cells, which are
dependent on the drug concentration. Data obtained
with the present study allow for a better characterization
of the effects of Dox on H9c2 myoblasts, used as a
model to study Dox-induced cardiotoxicity. The results
obtained also provide new and previously unknown
targets that can contribute to understand the mechanisms
involved in the cardiotoxicity of Dox.
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Introduction
Doxorubicin (Dox) is one of the most potent
antineoplastic drugs prescribed alone or in combina-
tion with other agents in the treatment of various
types of tumors. The antineoplastic mechanism of
Dox has been attributed to intercalation of the planar
anthracycline ring into the DNA helix (Box 2007)
and/or covalent binding to proteins involved in DNA
replication and transcription. Such interactions result
in inhibition of DNA, RNA, and protein synthesis,
leading ultimately to cell death (Cutts et al. 2005;
Cutts et al. 1996). However, clinical use of Dox is
restrained by a chronic and cumulative cardiotoxicity
that is manifested as a dilated congestive heart failure
(Takemura and Fujiwara 2007). Impaired body weight
gain and irreversible electrocardiogram alterations
(prolongation of ST and QT intervals) are observed
in rats 5 weeks after Dox administration (Villani et al.
1990). Decrease in left ventricular developed pres-
sure, increase in coronary perfusion pressure, ventric-
ular fibrillation, shortening of ventricular action
potential duration, reduction in cardiac index (cardiac
output/body weight), and an increase in total periph-
eral resistance were some other parameters altered in
rat and rabbit hearts in conjunction with morpholog-
ical and biochemical alterations after Dox treatment
(Joyeux et al. 2001; Potemski et al. 2006).
Marked dilation of the sarcoplasmic reticulum and
mitochondrial damage (Iwasaki and Suzuki 1991)
were previously observed in the myocardium after
Dox treatment. Contractile performance of atria is
significantly reduced, accompanied by myocyte
vacuolization and myofibrillar loss (Villani et al.
1990). Endomyocardial biopsies performed in human
hearts after Dox administration reveals an increase in
sarcoplasmic reticulum and T-tubule size, again
accompanied by cytoplasmic vacuolization. Nuclear
changes include clumping of chromatin and nucleolar
shrinkage, along with segregation of granular and
fibrillar components (Unverferth et al. 1981). These
alterations were reported to be more marked with
increasing dose of drug, but not with longer duration
of perfusion (Taylor and Bulkley 1982). Decreases in
contraction amplitude, velocity, and oxygen consump-
tion were also observed in cardiac myocytes isolated
from hearts of rabbits treated with Dox (Jones et al.
1990). Low myosin content was proposed to be
involved in the decreased contractility observed after
Dox treatment contributing to the reduced cardiac
output (Jones et al. 1990).
Generation of reactive oxygen species has been
proposed to be responsible for the toxicity of Dox (Xu
et al. 2001). In mitochondria, Dox is reduced to a
reactive semiquinone by complex I, reoxidizing to the
original form by univalent reduction of oxygen. The
process produces oxidative stress, which initially
mostly affects the mitochondria (Xu et al. 2001).
One result of Dox toxicity is apoptosis, whichmay be
responsible for cardiomyocyte death, although the exact
mechanism is still being investigated (Kalyanaraman
et al. 2002).
Animal models, primary cultures of cardiomyo-
cytes, and transformed cell lines have all been used to
investigate the mechanism by which Dox is selec-
tively cardiotoxic. The myoblastic cell line H9c2
(Kimes and Brandt 1976) is a well-characterized in
vitro system used to study Dox-induced biochemical
changes and the protective effect of a wide number of
compounds (Chua et al. 2006; L’Ecuyer et al. 2006;
Spallarossa et al. 2004; Wattanapitayakul et al. 2005).
For example, a recent study demonstrated that Dox
treatment leads to hypertrophy of H9c2 cells (Merten
et al. 2006), similar to what has been observed in
adult cardiomyocytes during the development of the
Dox-induced cardiomyopathy (Lushnikova et al.
2004). Despite some work conducted on the bio-
chemical alterations of H9c2 cells induced by Dox,
the evaluation and characterization of morphological
modifications has not been extensively studied.
The objective of this work was to assess, through
microscopy, alterations in cell morphology, which are
correlated with the appearance of apoptotic hallmarks
upon exposure of H9c2 myoblasts to Dox. With the
present study, it was also our intention to focus on
alterations in H9c2 cell morphology resulting from
exposure to several concentrations of Dox, which will
contribute to the understanding of the unique sensi-
tivity of cardiomyocytes to this anti-neoplastic agent.
Material and methods
Reagents Dulbecco’s modified Eagle’s medium
(DMEM), penicillin, streptomycin, fetal bovine se-
rum, and trypsin–ethylenediaminetetraacetic acid
(EDTA) were purchase from Gibco-Invitrogen (Grand
Island, NY, USA). Doxorubicin, dithiothreitol (DTT),
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phenylmethanesulfonyl fluoride (PMSF), and protease
inhibitor cocktail (leupeptin, antipain, chymostatin,
and pepstatin A) were obtained from Sigma (St Louis,
MO, USA). Caspases substrates and p-nitroanilide
(p-NA) were purchased from Calbiochem (San Diego,
CA, USA). Hoechst 33342, tetramethylrhodamine
methyl ester (TMRM), calcein-AM, propidium iodide
(PI), and N-(7)-nitrobenz-2-oxa-l,3-diazol-4-yl
(NBD)–phallacidin were obtained from Molecular
Probes (Eugene, OR, USA). Annexin V–fluorescein
isothiocyanate (FITC) was purchased from BD
Bioscience Pharmingen (San Diego, CA, USA).
MF20 and CMII23 antibodies were purchased from
Developmental Studies Hybridoma Bank, Iowa City,
IA, USA. The rabbit polyclonal antibodies to lamins
A/C and B1 were a gift from Dr. H. Worman
(Columbia University, NY, USA). Secondary anti-
body FITC-conjugated anti-mouse IgG antibody was
purchased from Jackson ImmunoResearch Laborato-
ries, Inc. (Cambridgeshire, UK).
Cell Culture The H9c2 cell line, originally derived
from embryonic rat heart tissue using selective serial
passages (Kimes and Brandt 1976), was purchased
from America Tissue Type Collection (Manassas, VA;
catalog no. CRL-1446). Cells were cultured in
DMEM supplemented with 1.5 g/l sodium bicarbon-
ate, 10% fetal bovine serum, 100 U/ml of penicillin,
and 100 μg/ml of streptomycin in 75 cm2 tissue
culture flasks at 37°C in a humidified atmosphere of
5% CO2. Cells were fed every 2–3 days and sub-
cultured once they reached 70–80% confluence. For
epifluorescence or confocal microscopy, cells were
seeded at a density of 35,000 cells per milliliter in
glass-bottom dishes (Mat-Tek Corporation, Ashland,
MA, USA). For lactate dehydrogenase (LDH) meas-
urements, H9c2 cells were seeded in 12-well plates
culture dishes at a subcultivation ration of 1:4. After
seeding, cells were allowed to grow for 3 days to
reach the desired confluence (>80–90%). For detec-
tion of phosphatidylserine (PS) exposure, chromatin
condensation studies and immunocytochemistry assay
cells were seeded in six-well plates containing glass
coverslips (final volume of 2 ml/well). For electron
microscopy and caspase-3- and caspase-9-like activity
measurement, cells were seeded in 75 cm2 tissue
culture flasks at a subcultivation ratio of 1:5. Cells
were then allowed to grow for 4–5 days to reach the
desired confluence (∽80–90%). Cells were seeded in
DMEM with 10% fetal bovine serum, and experi-
ments were carried out up to 24 h post-treatment. Dox
was directly added to the cell culture media at
described concentrations.
Cytoskeletal and sarcomeric labeling H9c2 cells,
seeded on glass coverslips in six-well plates, were
incubated with or without Dox for 24 h at the
indicated concentrations. For F-actin labeling, cells
were rinsed with cold phosphate-buffered saline
(PBS), fixed with 4% paraformaldehyde during
15 min at room temperature, rinsed again with PBS,
and stored in PBS Tween-20 (PBST) at 4°C until use.
For cardiac myosin heavy chain (MF-20 Antibody),
myosin IIB heavy chain (CMII23 antibody), and
lamins A/C and B1 immunolabeling, cells were fixed
and stored at −20°C in ice-cold absolute methanol.
Cells fixed with paraformaldehyde were permeabi-
lized with 0.2% Triton X-100 in PBS for 5 min at
room temperature after three washes with PBS. Cells
fixed with ice-cold methanol were rehydrated with
PBST during 5 min for three times. Cells were
incubated in blocking solution (PBST supplemented
with 1% non-fat powdered milk) for 30 min at 37°C,
probed with specific primary antibody (MF-20;
CMII23; lamin A/C, dilution 1:50; and lamin B1,
dilution 1:50) during 2 h at 37°C and stained with
FITC- or Texas Red-conjugated secondary antibody
(goat anti-rabbit for lamins A/C and B1, dilution 1:50;
and goat anti-mouse for MF-20 and CMII23, dilution
1:50), containing 5 μg/ml of Hoechst 33342, for an
additional 2 h at 37°C. Between labeling with primary
and secondary antibodies, cells were rinsed with
PBST three times during 5 min each. For F-actin
labeling, NBD-phallacidin was prepared following the
manufacturer’s instructions and supplemented with
sodium azide and Hoechst 33342 (0.05% and 5 μg/ml
final concentrations, respectively). The final working
solution was applied directly to the coverslips for 2 h
at 37°C. After labeling, coverslips were mounted on
glass slides in an anti-fade medium consisting of nine
parts glycerol and one part 0.1 M N-cyclohexyl-3-
aminopropanesulfonic acid buffer, pH 9.0, supple-
mented with 0.1% phenylenediamine and 0.1% 1,
4-diazabicyclo[2.2.2]octane (both from Sigma Chem-
ical Co.). Cells were observed by epifluorescence
microscopy using a Nikon Eclipse TE2000U micro-
scope. The fluorescein filter was used for FITC and
NBD-phallicidin imaging and the rhodamine filter for
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Texas Red fluorescence imaging. Images were obtained
using Metamorph software (Universal Imaging, Down-
ington, PA, USA).
Triple labeling of H9c2 cells with TMRM, Hoechst
33342, and calcein-AM, and visualization by confocal
microscopy H9c2 cells in glass-bottom dishes were
incubated with TMRM (100 nM), Hoechst 33342
(1 μg/ml), and calcein-AM (300 nM) for 30 min at
37°C in the dark. Due to the very low fluorescence of
the probes in the extracellular media, the images were
collected without replacing the cell culture media.
The images were obtained using a Nikon C-1 laser
scanning confocal microscope. TMRM signal was
acquired using a green He–Ne laser, the calcein-AM
signal was acquired using an air-cooled argon laser,
and the Hoechst signal was obtained by using a violet
diode laser. Differential interference contrast (DIC)
images using the confocal microscope were collected
using the air-cooled argon laser and the appropriate
detector.
Labeling of mitochondria in H9c2 cells with TMRM
and visualization by epifluorescence microsco-
py H9c2 cells in glass-bottom dishes were incubated
with TMRM (100 nM) for 30 min at 37°C in the dark.
Due to the very low fluorescence of the probes in the
extracellular media, the images were collected with-
out replacing the cell culture media. Cells were
observed by epifluorescence microscopy using a
Nikon Eclipse TE2000U microscope.
Analysis of nuclear alterations and cytoplasm vacuo-
lization in H9c2 cells Alterations in nuclear size and
the appearance of cytosolic vacuoles were observed
by microscope analysis by using phase contrast (×40
objective) or differential interference contrast (DIC,
×60 objective). Cells were seeded as described before
and treated with Dox for the chosen time points.
Image J 1.331 (NIH, USA) was used to measure the
size of cell nuclei. At least five random fields of view
were examined for each treatment group.
Electron microscopy of H9c2 cells After treatment,
trypsinized H9c2 cells were fixed for electron micros-
copy using 3% glutaraldehyde in 0.1 M sodium
cacodylate buffer, pH 7.3, for 2 h at 4°C. After
centrifugation (15,000 rpm, 3 min), pellets were washed
with 0.1 M sodium cacodylate buffer (pH 7.3). The
fixed and washed pellet was resuspended in 1% OsO4
buffered with sodium cacodylate 0.1 M, pH 7.3. After
2 h incubation, pellets were washed with cacodylate
buffer pH 7.3. Pellets were embedded in 1% agar,
subsequently dehydrated in a graded ethanol, and
embedded in Spurr’s resin. Ultrathin sections were
obtained with a LKB ultra-microtome Ultrotome III
and stained with methanolic uranyl acetate followed by
lead citrate and examined with a Jeol Jem-100SX
electron microscope operated at 80 kV.
Annexin V/PI assay Annexin V–FITC was used in
conjunction with a vital dye, PI, to distinguish
apoptotic (annexin V–FITC-positive, PI-negative) from
necrotic/late-apoptotic (annexin V–FITC-positive, PI-
positive) cells. After treatment with Dox, culture media
was removed, cells were washed twice with ice-cold
1× PBS and incubated with 100 μl of annexin V
incubation reagent (10 mM 4-2-hydroxyethyl-1-piper-
azineethanesulfonic acid (HEPES), pH 7.4, 150 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2
supplemented with 5 μg/ml PI and with annexin V–
FITC diluted 1:20) during 15 min at room temperature
in the dark. After two washes with 1× binding buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl,
1 mM MgCl2, 2.5 mM CaCl2), cells were observed by
fluorescence microscopy using an Nikon Eclipse
TE2000U epifluorescence microscope, and images
were obtained using Metamorph software (Universal
Imaging, Downingtown, PA, USA).
Caspase-like activity assay Total cellular extracts were
used for caspase activity assays. After Dox treatment,
H9c2 cells were harvested by trypsinization and
washed once with PBS. To collect total cells, two cen-
trifugation steps were performed for 5 min at 1,000×g.
Floating (dead) cells were also collected and combined
with adherent cells. Cellular pellets were resuspended
in collecting buffer (20 mM HEPES/NaOH, pH 7.5,
250 mM sucrose, 10 mM KCl, 2 mM MgCl2, 1 mM
EDTA) supplemented with 2 mM DTT, 100 μM
PMSF, and a protease inhibitor cocktail (containing
1 μg/ml of leupeptin, antipain, chymostatin, and
pepstatin A), and ruptured by 30 passages through a
27-gauge needle. The cell suspension was then rapidly
frozen/thawed three times in liquid nitrogen and kept at
−80°C until used. Protein content was assayed using the
Bradfordmethod. Tomeasure caspases-3- and caspases-
9-like activity, aliquots of cell extracts containing 25 μg
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(for caspase 3) or 50 μg (for caspase 9), total protein
were incubated in a reaction buffer containing 25 mM
HEPES (pH 7.4), 10% sucrose, 10mM DTT, 0.1%
3[(3-cholamidopropyl)dimethylammonio]-propanesul-
fonic acid, and 100 μM caspase substrate (Ac-DEVD-
pNA for caspase 3 or Ac-LEHD-pNA for caspase 9)
for 2 h at 37°C. Caspase-like activities were deter-
mined by following the detection of the chromophore
p-nitroanilide after cleavage from the labeled substrate
Ac-DEVD-p-nitroanilide or Ac-LEHD-p-nitroanilide.
The method was calibrated with known concentrations
of p-nitroanilide.
LDH measurements The integrity of plasma mem-
brane was determined by monitoring the activity of
cytoplasmic enzyme LDH in the extracellular incuba-
tion medium, which represents a common procedure to
determine membrane leakage and cellular damage.
Assessment of intracellular LDH was determined after
lysing the cells with 10 mM HEPES (pH 7.4) plus
0.01% Triton X-100 and freezing at −80°C. Cell debris
in both aliquots (intracellular and extracellular) were
removed by centrifugation at 14,000 rpm for 10 min.
LDH activity was determined spectrophometrically
(Jasco V-560, Jasco Corporation) by following the rate
of conversion of reduced nicotinamide adenine dinu-
cleotide at 340 nm, according to the method of
Bergmeyer and Bernt (Bergmeyer and Bernt 1974).
LDH released into the extracellular medium was
expressed as a percentage of the total LDH activity
in the cells [% of LDH released = extracellular LDH/
(extracellular LDH + intracellular LDH)].
Statistical analysis Data are expressed as mean ± SEM
for the number of experiments indicated in the legends
of the figures. Multiple comparisons were performed
using one-way analysis of variance followed by a
Bonferroni post hoc test. Significance was accepted
with p value<0.05.
Results
H9c2 myoblasts are spindle-to-stellate-shaped cells
that can be mono- or multi-nucleated (Fig. 1a).
Treatment with a low Dox concentration (1 μM) for
24 h leads to alterations in cell shape, which include
cell shrinkage starting from the periphery and
accompanied by membrane blebbing (Fig. 1b); round-
ing-up of cells, which is also accompanied by
membrane blebbing (Fig. 1c); and the appearance of
cells with multiple constrictions (Fig. 1d). H9c2
myoblasts treated with supra-physiological dosages
Fig. 1 Morphologic altera-
tions in H9c2 cells induced
by doxorubicin treatment.
a DIC images from untreat-
ed cells, showing normal
membrane morphology.
b–d DIC images from cells
treated with 1 μM Dox for
24 h. All four panels are the
same magnification. Scale
bar corresponds to 20 μm
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of Dox (5–50 μM) become vacuolated (Fig. 2a–d).
By using calcein-AM as a probe for cell viability, it
was observed that such cells still retain fluorescent
calcein, although the fluorophore was excluded from
the vacuoles (data not shown).
By using confocal microscopy (Fig. 3), alterations in
mitochondrial morphology were evaluated using
TMRM and correlated with cell viability by visualiza-
tion of intracellular calcein fluorescence. Figure 3a
shows control H9c2 myoblasts with intact cell mem-
branes and filamentous polarized mitochondria. Treat-
ment with 1 μM Dox causes the appearance of
membrane blebbing, which is accompanied by break-
age of the mitochondrial network (Fig. 3b). A
concentration of Dox as low as 0.5 μM promoted the
same basic alterations (data not shown). An event that
seems common to most cells is mitochondrial depolar-
ization induced by Dox, as assessed by loss of the
mitochondrial TMRM signal observed by epifluores-
cence microscopy (Fig. 3c–n). It is interesting that,
even for the highest Dox concentrations tested (20 and
50 μM), the mitochondrial network still accumulates
TMRM, demonstrating the retention of a transmem-
brane electric potential (Fig. 3m–p). Interestingly, most
of the mitochondrial alterations occur while cells retain
green calcein fluorescence, thus remaining viable.
Fig. 2 Doxorubicin induces
cytoplasm vacuolization for
supra-therapeutic concentra-
tions. Top DIC images
from a cells untreated and
cells treated with 10 μM
(b), 20 μM (c), and 50 μM
(d) Dox. All panels are the
same magnification. Scale
bar corresponds to 20 μm.
Images are representative
from three different cell
preparations. Bottom Statis-
tical analysis of the popula-
tion of control and treated
cells showing intracellular
vacuolization. Analysis was
performed by counting cells
showing vacuolization and
is expressed as the percent-
age of total cells counted.
Data represents the mean ±
SEM of five different
experiments. Statistical
analysis: *p<0.05 vs.
control
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To determine whether morphological changes
induced by lower Dox concentrations are associated
with changes in fibrous structural proteins, myosin
IIB, cardiac myosin, and F-actin organization were
examined in control and Dox-treated cells using
confocal microscopy. Exposure to 1 μM Dox for
24 h did not noticeably alter the appearance of F-actin
and myosin IIB. In contrast, the filamentous organi-
zation of cardiac sarcomeric myosin was altered at
both 0.5 and 1 μM Dox (Fig. 4). At these concen-
trations, Dox causes granulation and disorganization
of cardiac sarcomeric myosin in a number of cells. It
is interesting to note that the effects with 0.5 μM Dox
were more drastic than with 1 μM Dox, which can be
explained by protocol limitations, as detached cells
with more severe damage could not be imaged.
Nuclear alterations induced by Dox exposure were
also explored in the present work. Higher concen-
trations of Dox cause an increase in the area of cell
nuclei, which is statistically significant for 5 and
10 μM Dox (Fig. 5). The increase in nuclear area is
clearly observable by microscopy (Fig. 5a–d) and is
Fig. 3 Mitochondrial alterations in H9c2 cells induced by
doxorubicin treatment. a Laser scanning confocal microscopy
image from untreated cells showing triple labeling with
Hoechst 33342 (blue), calcein-AM (green), and TMRM (red).
b Laser scanning confocal microscopy showing the fluores-
cence of the three dyes after 24 h treatment with 1 μM Dox.
Note that part of the mitochondrial network is fragmented in
Dox-treated cells. c, d DIC and TMRM fluorescence of control
cells. e–n DIC and TMRM fluorescence of cells treated with
either 1 μM (e, f), 5 μM (g, h), 10 μM (i, j), 20 μM (k, l), or
50 μM (m, n) Dox. Images are representative from three to five
different experiments. Note that TMRM fluorescence appears
to be diminished with increasing concentrations of Dox;
nevertheless, mitochondrial still maintain some degree of
membrane polarization as evidenced by their ability to stain
with TMRM. Subpanels a and b are the same magnification;
the scale bar in a equals 5 μm. Subpanels e–n are the same
magnification; the scale bar in e equals 20 μm. c–n Obtained
by epifluorescence microscopy
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accompanied by what appears to be nucleoli disorga-
nization/dissolution (compare (Fig. 5a and d). An
increase in nuclear area was observed regardless the
degree of vacuolization shown by cells. Chromatin
condensation, a typical marker of apoptosis, was also
observable in some cells that appeared to be under-
going apoptosis (data not shown).
We then investigated whether the nuclear changes
were accompanied by alterations in the nuclear
lamina. Disruption of the lamina was detected after
a 24 h exposure to 1 μM Dox (Fig. 6). Changes in
lamin organization involved both lamin B1 and lamin
A/C. Alterations of the lamin structure are suggestive
of discontinuities or holes in the lamina meshwork,
indicating that Dox disrupts the organization of
lamins, either directly or as a consequence of cell
death processes.
Electron microscopy was used to gain insight into
structural changes caused by exposure to Dox for
24 h. For the lowest Dox concentration tested
(0.5 μM), no significant ultrastructural alterations
were found (Fig. 7a–d). Cells treated with 1 μM
Dox began to show mitochondrial alterations, includ-
ing enlargement and matrix disorganization (Fig. 7f
Fig. 4 Alterations of structural proteins induced by doxorubi-
cin in H9c2 cells. Confocal microscopy of the control and Dox-
treated (0.5 and 1 μM) H9c2 cells. After 24 h treatment, cells
were fixed and labeled with antibodies against myosin IIB
heavy chain (CMII23) and cardiac sarcomeric myosin heavy
chain (MF-20) or stained with NBD-phallacidin for F-actin
labeling. Cells were also counterstained with Hoechst for nuclei
labeling. Note that, although the structure of cardiac sarcomeric
myosin is disrupted, myosin IIB and f-actin are essentially
unaltered for the concentrations tested. Images are representa-
tive from three different cell preparations. Scale bar corre-
sponds to 20 μm
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and l). Cells treated with 20 μM Dox revealed loss of
mitochondrial cristae (Fig. 7g,h, and m) and nuclear
disorganization. Cytosolic vacuoles (Fig. 7g) become
apparent at this concentration. The highest Dox
concentration used (50 μM) is characterized by
visible cytoplasmic vacuoles and significant nuclear
alterations, which include chromatin decondensation
and disruption of the nuclear envelope (Fig. 7i,j,o).
For these high concentrations, mitochondria again
show generalized alterations, including cristae disar-
ray and swelling.
To correlate morphological alterations with bio-
chemical changes in H9c2 myoblasts, we investigated
if apoptotic markers, including PS exposure and
caspase activation, were present in cells treated with
different Dox concentrations. To examine whether PS
exposure occurs in H9c2 cells after Dox treatment,
control and treated cultures were dual-labeled with
annexin V and PI. Because PI is excluded from cells
with intact plasma membranes, it was used to
determine whether annexin V labeling was due to
externalization of PS or instead resulted from a loss of
Fig. 5 Alteration in nucleus
area in H9c2 cells treated
with doxorubicin. Top panel
DIC images of control H9c2
cells (a) or treated with 1
(b), 5 (c), and 10 μM (d)
Dox for 24 h, showing an
increase in nucleus size.
Images are representative
from four different experi-
ments. All images are the
same magnification; scale
bar=20 μm. Bottom panel
Statistical analysis of the
population of control cells
or cells treated with in-
creasing concentrations of
Dox for 24 h, showing an
increase in nuclear area.
Data analysis was per-
formed by quantifying nu-
clear area as square pixels.
Data represent the mean ±
SEM of four different cell
preparations. Statistical
analysis: *p<0.05 vs. un-
treated cells
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membrane integrity. Dox causes the appearance of PS
in the outer leaflet of the cell membrane as early as
6 h after addition (Fig. 8), showing an increase from
4% in the control to 14.5% in cells treated with
0.5 μM Dox and to 27.8% after treatment with 1 μM
Dox. Only the treatment with 1µM Dox was
statistically significant. Less than 1% of the cells
showed PI labeling, indicating that membrane integ-
rity is maintained in apoptotic cells at this time point.
However, for a longer exposure time (12 h), necrotic/
late-apoptotic cells are detected by PI staining,
showing an increase from 0% in control to 2.7%
after 0.5 μM Dox treatment and to 5.0% in cells
treated with 1 μM Dox, although the differences were
not statistically significant. However, for this time
point, an increase in the percentage of cells showing
annexin V labeling after Dox treatment was also
observable. A significant increase of 31.6% and
27.3% was observed after treatment with 0.5 and
1 μM Dox, respectively. The present results confirm
that Dox at low concentrations causes PS exposure
typical of apoptosis in H9c2 myoblasts. In contrast,
cells undergoing necrosis appear to be a small
minority at these Dox concentrations and time points.
LDH release assays confirmed that, at lower Dox
concentrations, cell membrane intactness (suggesting
necrosis) is only compromised for 1 μM (Fig. 9c,
12.5±3.4% vs. 23.2±1.8% release). The results from
Fig. 9c also demonstrate that, for 5 and 10 μM Dox,
no further enhancement in the percentage of LDH
release was observed. No LDH release was detected
for any concentration tested when cells were treated
for 6 and 12 h. By using epifluorescence microscopy,
the presence of necrotic cells was confirmed by the
absence of calcein accumulation and increased nucle-
ar labeling with ethidium homodimer (data not
shown).
Caspases were activated upon treatment with Dox,
not only for lower (1 μM) but also for higher Dox
concentrations (5 and 10 μM), especially for a 24-
h incubation period (Fig. 9a and b). For a 6-h time
period, an increase in caspase 9 activity was only
observed after treatment with 10 μM Dox. In contrast,
no caspase 3 activity was detected for this time point
regardless of the Dox concentration used. However,
after 12 h treatment, an increase in the activity of both
caspases 3 and 9 was observed for all Dox concen-
trations tested.
Discussion
Doxorubicin is a potent antineoplastic agent whose
clinical use is restricted by a cumulative and serious
cardiac toxicity. Numerous studies have been per-
formed to understand why Dox is selectively cardio-
toxic. In vivo models of Dox-induced cardiomyopathy
(Oliveira and Wallace 2006; Santos et al. 2002) and in
Fig. 6 Alteration of nuclear
lamina induced by doxoru-
bicin treatment. Epifluores-
cence microscopy of H9c2
nucleus after treating cells
with 1 μM Dox for 24 h.
After treatment, cells were
fixed and labeled with anti-
bodies against lamin A/C
and lamin B. Images are
representative from three
different cell preparations.
Scale bar corresponds to
10 μm
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vitro studies using primary cardiomyocytes (Gabriel-
son et al. 2007; Solem et al. 1996; Zhou et al. 2001)
or other cell lines (L’Ecuyer et al. 2001; Spallarossa et
al. 2004) have been widely reported in the literature.
From the different models used, some conclusions are
common to all: (a) Dox is activated at the mitochon-
drial level, forming a semiquinone radical, and (b)
Dox causes oxidative stress in cardiac cells that
particularly affects mitochondria (Berthiaume and
Wallace 2007; Wallace 2003).
One of the cell lines used to study Dox toxicity is
the myoblastic cell line H9c2, originally derived from
embryonic rat heart tissue by using selective serial
passages (Kimes and Brandt 1976). H9c2 cells have
Fig. 7 Electron microscopy
of H9c2 cells after 24 h
treatment with doxorubicin.
a and b Control; c and
d 0.5 μM Dox; e and f
1 μM Dox; g and h 20 μM
Dox; i and j 50 μM Dox.
k–m Comparison of mito-
chondria from control cells
(k) and cells treated with
1 μM (l) and 50 μM (m)
Dox. n and o Comparison
of nuclear envelope mor-
phology between control
cells (n) and cells treated
with 50 μM Dox (o). Note
the discontinuity of the nu-
clear envelope and the
decondensed appearance of
the chromatin in j and o.
Subpanels a, c, e, g, and i
have the same magnification
(bar corresponds to 4 μm).
The white bar in b corre-
sponds to 7.5 μm, which is
the same magnification as d,
f, h, and j. Subpanels k–m
are the same magnification
(bar equals 2 μm). Bar in n
equals to 1 μm (same mag-
nification of o). n nucleus,
m mitochondria, v vacuole.
The white arrow in i points
to disruption of the nuclear
membrane
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been used to study several aspects of Dox interaction
with cardiac cells, including the intracellular degra-
dation of the anthracycline (Menna et al. 2007), DNA
damage induced by Dox (L’Ecuyer et al. 2006), or
p53 activation (Chua et al. 2006) among others. On
the other hand, this same cell line has been used as a
model to investigate the protective effect of several
compounds against Dox-induced cardiotoxicity.
Among such compounds, carvedilol (Spallarossa et
al. 2004), rosmarinic acid (Kim et al. 2005), plantai-
noside D (Kim et al. 2007), or thrombopoietin (Li et
al. 2006) are particular examples.
Despite biochemical data gathered on signaling
pathways involving Dox-induced H9c2 cell dysfunc-
tion, relatively little is known regarding alterations in
cell morphology. It was the objective of the present
work to conduct an investigation on the morpholog-
ical alterations that H9c2 myoblasts display upon Dox
treatment. For this purpose, several Dox concentra-
tions were used in the present study. The lowest ones
(0.5 and 1 μM) can be considered clinically relevant
because they fall well within the concentrations of
Dox found in the plasma of patients undergoing Dox
therapy (Frost et al. 2002). Intermediary concentra-
tions such as 5 and 10 μM are unlikely to be achieved
in vivo, except in individuals with low drug clearance
or immediately after drug administration (Frost et al.
2002; Palle et al. 2006). Finally, 20 and 50 μM are
largely supra-physiological concentrations of Dox; the
main purpose for their use was to investigate if higher
drug doses could uncover mechanisms of Dox-
induced cytotoxicity that would be harder to detect
with lower, more clinically relevant, concentrations.
From the results obtained in the present study, it
was confirmed that Dox leads to caspase activation at
concentrations up to 10 μM (Fig. 9). Caspase 9 is
Fig. 8 Doxorubicin induces the translocation of phosphatidyl-
serine to the outer leaflet of the cellular membrane. a After 6
and 12 h, the control and Dox-treated (0.5 and 1 μM) cells were
labeled with Annexin V and propidium iodide. Panels represent
phase contrast images of H9c2 cells merged with corresponding
epifluorescence microscopy images of propidium iodide (red)
and Annexin V (green). Images are representative from three
separate experiments. All images have the same magnification;
scale bar=20 μm. b Statistical analysis of the population of
control cells or cells treated with increasing concentrations of
Dox, showing the relation between treatment and annexin V/
propidium iodide labeling. Analysis was performed by counting
cells without any labeling (healthy cells), annexin V labeling
(apoptotic cells), and PI/Annexin V double labeling (necrotic
and or/late apoptotic cells). Data represent the mean ± SEM of
three different cell preparations. Statistical analysis: p<0.05 vs.
control relatively to healthy (asterisk) and apoptotic cells
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dependent on the mitochondrial pathway for apopto-
sis (Garrido et al. 2006; Schafer and Kornbluth 2006),
confirming that mitochondria are involved in Dox-
induced toxicity on H9c2 myoblasts. In fact, both
mitochondrial-dependent (Ueno et al. 2006) and
mitochondrial-independent (Jang et al. 2004) path-
ways have been described as involved in in vivo
apoptosis induced by Dox in cardiac cells. LDH
release assays also confirmed that Dox causes cell
death, although the method itself measures necrosis,
which can occur in vitro sequentially to apoptosis
induction or occur as a primary event. Markers of
apoptosis could be detected as early as 6 h after Dox
treatment, and the relatively low numbers of cells
with compromised membranes at these early time
points suggest that the necrotic events observed in this
study reflect the latter stages of apoptosis. No LDH
release, detected for 0.5 μM Dox during 24 h, is
suggestive that, for this concentration, apoptosis is the
leading mechanism. The sum of results for caspase
activity and LDH release regarding 1 μM Dox
suggest that, for 24 h, a major transition between
apoptosis and necrosis occurs.
It was demonstrated that Dox causes profound
morphological changes in H9c2 myoblasts. Rounding
up of the cell body, cellular membrane blebbing, and
phosphatidylserine (PS) translocation from the inner
to the outer leaflet of the plasma membrane are some
alterations observed in H9c2 myoblasts after Dox
exposure. In fact, alterations in plasma membrane
asymmetry are one of the characteristic features of
cells undergoing apoptosis. In apoptotic cells, phos-
phatidylserine (PS) is translocated from the inner to
the outer leaflet of the plasma membrane, serving as a
recognition signal for macrophages (Fadeel and
Kagan 2003). Such morphological alterations resem-
ble the shape changes displayed by cardiomyocytes
(Yue et al. 1998) or H9c2 myoblasts (Sardão et al.,
Fig. 9 Incubation of doxorubicin with H9c2 cells for 24 h
increases caspases-9- and caspases-9-3-like activation and
reduces cell viability. Caspase-9- (a) and caspase-3-like (b)
activities were measured by following the cleavage of the
colorimetric substrates Ac-LEHD-pNA and Ac-DEVD-pNA,
respectively. The caspase-like activity was expressed as
concentration of pNA released per microgram protein. The
results were calibrated with known concentrations of pNA. c
Cellular viability was determined by the LDH leakage assay, as
described in the methods section. The results were expressed as
percentage of total LDH released and represent the means ±
SEM of six independent experiments. Statistical analysis: *p<
0.05 compared with untreated cells for the same time point
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unpublished data) when incubated with the protein
kinase inhibitor staurosporin. Although Yue et al.
(1998) reported staurosporin-induced apoptosis in
cardiomyocytes with caspase 3 activation, it is likely
that different compounds with distinct mechanisms of
action may cause similar morphological alterations.
The data from the present work also demonstrate for
the first time that Dox alters the organization of H9c2
myoblast cardiac sarcomeric myosin. No changes
were observed on myosin IIB or f-actin organization.
A relation between Dox treatment and alterations in
myocardial structural proteins and regulatory protein
expression was previously described after in vivo
treatment of rats (Dudnakova et al. 2003). It is also
possible that Dox directly binds to cardiac myosin,
thus altering its normal organization. It is unclear
whether the structural disorganization of the filamen-
tous network of cardiac myosin was a cause or
consequence of the changes in cell morphology
induced by Dox treatment. However, the demonstra-
tion that cardiac sarcomeric myosin organization was
more noticeably perturbed than myosin IIB or f-actin
organization raises the intriguing possibility that
cardiac sarcomeric myosin may be a specific target
that contributes to the unique sensitivity of cardiac
tissue to the toxic effects of Dox.
Among the nuclear effects of Dox treatment, a
marked disruption of the nuclear lamina, involving
both A- and B-type lamins was observed. Lamins are
well-known caspase substrates (Croft et al. 2005), and
it is possible that the lamin alterations observed in this
study are a reflection of apoptosis (Lieberman and
Fan 2003; Prasad et al. 1999). von Harsdorf et al.
(1999) detected lamin degradation induced by oxida-
tive stress in isolated cardiac cells, suggesting a link
between Dox-induced oxidative stress and degrada-
tion of the nuclear lamins. Lamins are interesting
putative Dox targets for a number of reasons.
Mutations in lamin A/C are a direct cause of muscular
dystrophy, one symptom of which is cardiac dysfunc-
tion and pathology (Ben Yaou et al. 2006; Muntoni
2003). However, lamin A/C mutations usually take a
number of years to result in mortality (Perrot et al.
2006), which is not unlike the delayed and cumulative
nature of Dox cardiotoxicity. Nuclear lamin function
has been linked to the regulation of DNA organiza-
tion, DNA synthesis, and gene expression, and it has
been suggested that disruptions in the nuclear lamina
can have long-term effects on overall gene expression
patterns in cells (Bridger et al. 2007). Also, mutations
in lamins can lead to progeria or premature aging
syndromes (Dechat et al. 2007). It appears that Dox
interaction with nuclear lamins is worth further
attention.
Another nuclear-associated Dox effect was an
increase in nuclear area. This increase was visible
for 5 μM Dox, which is within the upper limits of
Dox concentrations normally found in the plasma of
patients (Frost et al. 2002; Palle et al. 2006). Similar
nuclear swelling has been described after etoposide
treatment of neuronal cells (Kim et al. 2001); like
Dox, etoposide is known to have topoisomerase II
inhibitory activity. Changes in nuclear morphology,
including chromatin decondensation, were also ob-
served by electron microscopy (EM). Dox has been
reported to produce both an unfolding of the overall
chromatin structure as evidenced by the increased
production of acid-soluble oligonucleotides and a
disruption of the core particle structure with increased
production of DNA of subnucleosomal size and
smearing of the nucleosome pattern (Grimmond and
Beerman 1982). The observation may explain the
profound nuclear alterations induced by higher Dox
concentrations. Rupture of the nuclear envelope was
also observed starting at 10 μM Dox. Changes in
nuclear envelope morphology may be related to the
effects of Dox on the lamina noted above.
Mitochondria are known targets of Dox; in vivo
studies (Santos et al. 2002) demonstrate that Dox
induces mitochondrial swelling in cardiac tissue. In
the present study, although 0.5 μM Dox did not
promote significant mitochondrial alterations as ob-
served by electron microscopy, 1 μM Dox caused
structural alterations in a subset of mitochondria,
which included organelle enlargement. Morphological
changes are more evident at higher Dox concentra-
tions, where cristae content is reduced and severely
damaged mitochondria are observed. In fact, it was
difficult to distinguish by EM the difference between
the vacuoles found for higher Dox concentrations and
swollen mitochondria (see Fig. 7j). By using confocal
and epifluorescence microscopy to investigate mito-
chondrial alterations during Dox incubation, it is
concluded that Dox causes (a) mitochondrial depolar-
ization and (b) fragmentation of mitochondrial fila-
ments, both of which are more common in cells
displaying membrane blebbing (even for the lowest
Dox concentration tested). It appears that the abnor-
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mal mitochondrial morphology as observed by elec-
tron microscopy is correlated with a reduction in
TMRM staining and, thus, a reduction in electric
potential. For the largest Dox concentrations used (20
and 50 μM), although severe mitochondrial damage is
observable by electron microscopy, polarized mito-
chondria can still be found in cells. Mitochondrial
swelling can result from induction of the mitochon-
drial permeability transition (MPT). The MPT is a
condition triggered by excessive mitochondrial calcium
loading and oxidative stress; one of the final results is
mitochondrial swelling due to osmotic equilibrium
between the mitochondrial matrix and the cytosol
(Rasola and Bernardi 2007). Dox causes oxidative
stress in cardiac muscle (Davies and Doroshow 1986),
and oxidative stress has previously been shown to
induce the MPT in H9c2 myoblast mitochondria (Park
et al. 2003). Therefore, it is reasonable to presume that
the mitochondrial morphological changes observed in
this study arise, at least in part, by the ability of Dox to
induce the permeability transition in a mitochondrial
sub-population that would be more extensive as Dox
concentration increases.
The vacuoles observed at higher Dox concentra-
tions (Fig. 2) could have originated from sarcoplasmic
reticulum enlargement (Iwasaki and Suzuki 1991) or
produced by autophagic cell death (Yan et al. 2005)
triggered by the large Dox concentrations used. In
many cell lines, such vacuoles are known to contain
products of lipid metabolism or peroxidation (Shima-
saki et al. 1984; Terman and Brunk 2005).
In conclusion, the present work describes several
morphological alterations displayed by H9c2 myo-
blasts after Dox treatment. For lower Dox concen-
trations, which are to be found in patients receiving
Dox therapy, Dox causes morphological alterations
(e.g., lamin degradation, cardiac sarcomeric myosin
disorganization) that occur simultaneously with
markers of apoptosis (caspase activation or PS
exposure). H9c2 myoblast cells display heteroge-
neous morphological alterations, although maintain-
ing membrane integrity during the initial stages of the
apoptotic process. Higher concentrations of Dox that
are in the top-most limit found in the serum of
patients (Frost et al. 2002) or that are supra-
physiological caused different morphological altera-
tions that include nuclear swelling and the formation
of vacuoles. It is pertinent to speculate that the same
effects could be attained in vivo using a subchronic or
chronic treatment with lower, pharmacological doses
due to tissue drug accumulation. In fact, most
alterations induced by Dox on H9c2 myoblasts, such
as mitochondrial and nuclear damage, cytoplasm
vacuolization, alterations in sarcomeric proteins, and
apoptosis, are indeed observed in cardiac tissue after
in vivo Dox treatment (Grimmond and Beerman
1982; Iwasaki and Suzuki 1991; Jang et al. 2004;
Jones et al. 1990; Ueno et al. 2006; Unverferth et al.
1981; Villani et al. 1990).
However, for the first time, the present study
describes alterations in sarcomeric protein organiza-
tion and identifies nuclear lamina proteins as potential
Dox-targets; such alterations should be looked for on
differentiated mature cardiac myocytes. In fact, one of
the limitations of the present work is the fact that the
H9c2 cell line is phenotypically distinct from cardiac
myocytes, even though they share several properties
(Hescheler et al. 1991; Kimes and Brandt 1976).
Although this myoblastic cell line shows similar
morphological characteristics to immature embryonic
cardiomyocytes, it has been shown to retain several
electrical and hormonal signaling pathways found in
adult cardiomyocytes and is, therefore, a useful model
for studying various aspects of cardiomyocyte phys-
iology and pathophysiology (Brostrom et al. 2000;
Wayman et al. 2001). One particular question cur-
rently under study in our laboratory is if differences in
cell proliferation observed in undifferentiated vs.
differentiated H9c2 cells can alter the susceptibility
to Dox or if these same morphological changes occur
in non-cardiac cells exposed to Dox in culture.
Data obtained from the present work complements
previous works demonstrating pathways activated or
inhibited by Dox on H9c2 myoblast cells and
suggests that previously unknown Dox targets, such
as nuclear lamins can contribute to the pathophysiol-
ogy of Dox cardiotoxicity.
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